Keyword: Regeneron Pharmaceuticals
Decibel Therapeutics raised $55 million in a series C round and named Vir Biotechnology CEO George Scangos as chair of its board of directors.
At BIO, we chatted with Doug Ingram about Sarepta's pipeline, its latest hires and how the healthcare landscape must change.
Sarepta brought on Biogen’s VP of late-stage programs, Gilmore O’Neill, as chief medical officer, after their previous hire left after 8 months.
Our rolling live blog for all the biotech news that's fit to print from J.P. Morgan. Check here frequently for ongoing updates.
The project will see Regeneron sequence the exomes of 500,000 Britons with the financial backing of AbbVie, Alnylam, AstraZeneca, Biogen and Pfizer.
Regeneron and Sanofi’s PD-1 candidate cemiplimab will be tested alongside a human papillomavirus (HPV) targeting drug from Dutch biotech ISA Pharma.
Sanofi and Regeneron have touted new topline data for their midstage checkpoint inhibitor in a certain form of skin cancer this morning.
Decibel forged an alliance with Regeneron that lets it access the big biotech’s scientific expertise without losing rights to its drug candidates.
The decision follows data from two phase 2 trials that tested angiopoietin 2 antibody nesvacumab in combination with Eylea.
After posting positive results from a midstage test of its oral immunotherapy AR101 last spring, Aimmune Therapeutics will try out its peanut allergy medication in combination with Sanofi/Regeneron’s Dupixent (dupilumab).